Chitosan-based nanoconjugated hormone delivery boosts reproductive efficiency in male Labeo rohita.
Malik. Mohd Ashraf MA; Gupta. Subodh S; Varghese. Tincy T; Jahageerdar. Shrinivas S; Nayak. Sunil Kumar SK; Reang. Dhalongsaih D
Key Findings
- Chitosan nanocarriers protect GnRH‑a from rapid breakdown and reduce injection stress in fish.
- Full‑dose nanoconjugated GnRH‑a plus domperidone gave the highest milt volume, sperm motility, and sperm count compared to the commercial product.
- Half‑dose nanoconjugated GnRH‑a achieved similar results to the commercial hormone, indicating dose‑reduction is possible.
Practical Outcomes
- For most biohackers, the results aren’t directly usable because they involve fish breeding, not human health. However, the work shows that chitosan nanocarriers can improve hormone stability and allow lower dosing, which could inspire similar delivery approaches for human peptide therapies.
Summary
The study tested a new way to give a fish hormone using tiny chitosan particles, which kept the hormone stable and let researchers use lower doses while still boosting sperm production in male fish. Adding a drug called domperidone made the effect even stronger, and the half‑dose worked almost as well as the standard commercial hormone.
Abstract
Hormone-induced breeding is pivotal in freshwater aquaculture, yet conventional gonadotropin-releasing hormone analogues (GnRH-a) are limited by their rapid degradation and cause stress associated with high-dose injections. Chitosan nanocarriers offer improved hormone stability and delivery. This study evaluated the reproductive efficacy of chitosan nanoconjugated salmon GnRH-a (ChN-sGnRH-a), alone or with domperidone, in male Labeo rohita. Six treatments were tested: Cn (Negative control, nanocarrier control), Cp (Positive control, commercial GnRH-a: Gonopro-FH® at 0.1 ml/kg), T1 (ChN-sGnRH-a at full dose, 0.1 ml/kg), T2 (T1 + domperidone 10 mg/ml), T3 (ChN-sGnRH-a at half dose, 0.05 ml/kg), and T4 (T3 + domperidone 10 mg/ml). T2 resulted in significantly higher (P < 0.05) relative milt volume (8.11 ± 0.47 ml/kg), sperm motility (85.7 ± 1.8 %), and sperm count (3.97 ± 0.05 × 10 ¹⁰/ml) compared to Cp. Serum testosterone (5.2 ± 0.3 ng/ml), 11-ketotestosterone (4.8 ± 0.2 ng/ml), and 17α,20β-dihydroxyprogesterone (2.1 ± 0.1 ng/ml) peaked at 12 h post-injection in T2, sustaining elevated levels over 18 h. T2 also showed significantly (P < 0.05) higher expression of fshβ, lhβ, fshr, and lhr genes, along with advanced testicular histoarchitecture marked by abundant spermatozoa and active leydig/sertoli cells. Principal component analysis revealed that T2, T4 and Cp grouped separately with more than 97 % variance covered by reproductive indices. Notably, T4 (half-dose) was comparable to Cp, suggesting efficacy at reduced hormone dosage. Overall, the findings demonstrate that full-dose ChN-sGnRH-a coadministered with domperidone is superior to commercial GnRH-a, and half-dose nanoconjugates provide equal efficacy, justifying a dose-reduction regime for sustainable, low-stress broodstock management of L. rohita.
Study Information
pubmed
2025
2025-11-10T00:00:00.000Z
10.1016/j.anireprosci.2025.108041
47